Clinical Trial Update: A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) [Phase 2]

View source ↗

Summary

Phase 2 trial update of omalizumab (Xolair) in patients with chronic idiopathic urticaria who remain symptomatic despite antihistamines; the study is completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Chronic Idiopathic Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2011-09-09